Simplifying Global Compliance
AstraZeneca Faces DOJ Probe Into Brilinta Phase III Clinical Trial
The Department of Justice is investigating a Phase III study of AstraZeneca’s (AZ) heart drug Brilinta, which analysts and experts say could revolve around allegations of data falsification.
To View This Article:
Buy This Article Now
Copyright ©2017. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing